Brief: UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
16/01/2025 13:40
Jan 16 (Reuters) - Ucb SA UCB.BR :
* UCB ANNOUNCES U.S. AVAILABILITY OF 320 MG/2 ML
SINGLE-INJECTION
ADMINISTRATION OPTION FOR BIMZELX® (BIMEKIZUMAB-BKZX)
Source text: ID:nPn8NpRwXa
Further company coverage: UCB.BR
((Reuters.Briefs@thomsonreuters.com;))
Recent news on UCB SA
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: UCB Announces Data Showing Positive Impact Of Kygevvi In Tk2d Patients
Brief: UCB Completes $2.2 Billion Acquisition Of Candid Therapeutics
Europe Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside